← Search & browse all drugs
VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Drugs for treatment of hyperkalemia and hyperphosphatemia
lanthanum carbonate
V03AE03
Forms & Strengths
- Chewable tablet: 500 mg, 750 mg, 1000 mg elemental lanthanum
Adult Dosing
- Initial dose: 750 mg to 1500 mg daily administered orally in divided doses with meals
- Titration: Titrate every 2-3 weeks based on serum phosphate levels, usual maintenance range 1500 mg to 3000 mg daily
Pediatric Dosing
- Safety and efficacy in pediatric patients below the age of 18 years have not been established
Indications
- Reduction of serum phosphate in patients with end-stage renal disease (ESRD)
Mechanism of Action
- Binds dietary phosphate in the gastrointestinal tract, forming insoluble lanthanum phosphate complexes that are excreted in feces, thereby decreasing systemic phosphate absorption
Contraindications
- Bowel obstruction
- Fecal impaction
- Ileus
- Known hypersensitivity to lanthanum carbonate
Adverse Reactions
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Constipation
- Hypocalcemia
Drug Interactions
- May decrease absorption of oral medications such as quinolones, tetracyclines, and levothyroxine; separate administration by at least 2 hours
Curated Content: Needs Vetting Before Put to Clinical Use